OPKO Health, Inc. (OPK)
NASDAQ: OPK · Real-Time Price · USD
1.210
+0.010 (0.83%)
At close: Apr 28, 2026, 4:00 PM EDT
1.150
-0.060 (-4.96%)
After-hours: Apr 28, 2026, 4:34 PM EDT
OPKO Health Revenue
In the year 2025, OPKO Health had annual revenue of $606.88M, down -14.90%. OPKO Health had revenue of $148.45M in the quarter ending December 31, 2025, a decrease of -19.16%.
Revenue (ttm)
$606.88M
Revenue Growth
-14.90%
P/S Ratio
1.51
Revenue / Employee
$266,760
Employees
2,275
Market Cap
918.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 606.88M | -106.26M | -14.90% |
| Dec 31, 2024 | 713.14M | -150.35M | -17.41% |
| Dec 31, 2023 | 863.50M | -140.70M | -14.01% |
| Dec 31, 2022 | 1.00B | -770.52M | -43.42% |
| Dec 31, 2021 | 1.77B | 339.31M | 23.64% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 824.50M |
| NeoGenomics | 727.33M |
| Veracyte | 517.15M |
| GeneDx Holdings | 427.54M |
| CareDx | 379.81M |
| Castle Biosciences | 344.23M |
| Fulgent Genetics | 322.67M |
| BillionToOne | 305.11M |
OPK News
- 43 minutes ago - OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results - GlobeNewsWire
- 6 days ago - OPKO Health's ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas - GlobeNewsWire
- 7 days ago - OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026 - GlobeNewsWire
- 2 months ago - OPKO Health to Participate in the Jefferies Biotech on the Beach Summit - GlobeNewsWire
- 2 months ago - OPKO Health Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire
- 2 months ago - OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 - GlobeNewsWire
- 2 months ago - OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism - GlobeNewsWire